Drug-induced liver injury: Icelandic lessons

Gastroenterology

Volumn 144, Issue 7, 2013, Pages 1335-1336

  Hoofnagle, Jay H ^a,b   Navarro, Victor J ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Division of Hepatology and Liver Transplantation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; AZATHIOPRINE; BETA INTERFERON; COTRIMOXAZOLE; DICLOFENAC; DOXYCYCLINE; INFLIXIMAB; ISONIAZID; ISOTRETINOIN; METHOTREXATE; NITROFURANTOIN; PHENYTOIN; SIMVASTATIN;

EDITORIAL; HUMAN; ICELAND; INCIDENCE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; TOXIC HEPATITIS;

EID: 84878274083     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.04.026     Document Type: Editorial

References (12)

1. National Institutes of Health Clinical and research information on drug-induced liver injury www.LiverTox.nih.gov Accessed March 6, 2013
2. R.J. Fontana, L.B. Seeff, R.J. Andrade Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop Hepatology 52 2010 730 742
3. E.S. Björnsson, O.M. Bergmann, H.K. Björnsson Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland Gastroenterology 144 2013 1419 1425
4. C. Sgro, F. Clinard, K. Ouazir Incidence of drug-induced hepatic injuries: a French population-based study Hepatology 36 2002 451 455
5. L. Ibanez, E. Perez, X. Vidal Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs J Hepatol 37 2002 592 600
6. F.J. De Abajo, D. Montero, M. Madurga Acute and clinically relevant drug-induced liver injury: a population based case-control study Br J Clin Pharmacol 58 2004 71 80
7. G. Danan, C. Benichou Causality assessment of adverse reactions to drugs-I A novel method based on the conclusions of International Consensus Meeting: application to drug-induced liver injuries J Clin Epidemiol 46 1993 1323 1330
8. N. Chalasani, R.J. Fontana, H.L. Bonkovsky Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States Gastroenterology 135 2008 1924 1934
9. R.J. Andrade, M.I. Lucena, M.C. Fernandez Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period Gastroenterology 129 2005 512 521
10. A. Reuben, D.G. Koch, W.M. Lee Acute Liver Failure Study Group Drug-induced acute liver failure: results of a U.S. multicenter, prospective study Hepatology 52 2010 2065 2076
11. V.J. Navarro Herbal and dietary supplement hepatotoxicity Semin Liver Dis 29 2009 373 382
12. A.K. Daly, P.T. Donaldson, P. Bhatnagar HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat Genet 41 2009 816 819